The differences of Xpert MTB/RIF and BACTEC MGIT960 in detecting Mycobacterium tuberculosis and Rifampin resistance
CHEN Junlin1 HUANG Fei1 XU Feifan1 GU Delin1▲ HU Zhongyi2
1.Department of Tuberculosis Medical, the Sixth People's Hospital of Nantong, Jiangsu Province, Nantong 226011, China；
2.Department of Laboratory, Shanghai Pulmonary Hospital, Affiliated to Tongji University, Shanghai 200433, China
Abstract：Objective To explore the differences between Xpert MTB/RIF and BACTEC MGIT960 in detecting Mycobacterium tuberculosis (MTB) and Rifampin (RFP) resistance. Methods From June 2014 to June 2017, sputum specimens from 188 retreated smear positive pulmonary tuberculosis patients in the Sixth People's Hospital of Nantong were selected as research objects. Xpert MTB/RIF and BACTEC MGIT960 were used to detect MTB in the sputum specimens of the patients and the RFP resistance was analyzed combined with the medical history. Results Then were 146 cases of consistency results between Xpert MTB/RIF and BACTEC MGIT960 in detecting MTB, while 38 cases of heterogeneity. The number of cases in Xpert MTB/RIF group was higher than that of BACTEC MGIT960 group in the use of the drug with rifamycin and the duration above 3 months, with statistically significant difference (χ2=6.31，P ＜ 0.05). There were no statistically significant differences between Xpert MTB/RIF and BACTEC MGIT960 in the comparison of other medical history groups (P ＞ 0.05). Conlusion The results of Xpert MTB/RIF and BACTEC MGIT960 in detecting MTB and RFP resistance from sputum specimens of smear positive are differential. It may be associated with medical history of the patients. Clinical physicians should pay attention to the differences of the two detection methods and formulate anti-tuberculosis treatment plan accurately.
[1] Herve C，Bergot E，Veziris N，et al. Tuberculosis in 2015：From diagnosis to the detection of multiresistant cases [J]. Rev Mal Respir，2015，32（8）：784-790.
[2] World Health Organization. Treatment Guidelines for Drug-resistant Tuberculosis. 2016 Update.WHO/HTM/TB/2016. 04.Geneva：World Health Organization.2016.
[3] 马俊锋，陆峰，王小平，等.2009-2014年南通市结核分枝杆菌的耐药流行状分析[J].现代预防医学，2017，44（2）：328-331.
[4] Arora J，Singhal R，Verma AK，et al. Isoniazid resistance among rifampicin-susceptible Mycobacterium tuberculosis isolates from tuberculosis patients [J]. Int J Mycobacteriol，2016，5（1）：127-128.
[5] Catanzaro A，Rodwell TC，Catanzaro DG，et al. Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis [J]. PLoS One，2015，10（8）：e0 136 861.
[6] 张玉华，张国钦，钟达，等.应用Xpert MTB/RIF法对我国肺结核诊断及利福平耐药检测的Meta分析[J].现代预防医学，2017，44（12）：2116-2119.
[7] Walters E，van der Zalm MM，Palmer M，et al. Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease [J]. Pediatr Infect Dis J，2017，36（9）：837-843.
[8] 中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京：中国教育文化出版社，2006.
[9] Sah AK，Joshi B，Khadka DK，et al. Comparative Study of GeneXpert MTB/RIF Assay and Multiplex PCR Assay for Direct Detection of Mycobacterium tuberculosis in Suspected Pulmonary Tuberculosis Patients [J]. Curr Microbiol，2017，74（9）：1026-1032.
[10] You JH，Lui G，Kam KM，et al. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area [J]. J Infect，2015，70（4）：409-414.
[11] Hu PL，Bai LQ，Liu FG，et al. Evaluation of the Xpert MTB/RIF assay for diagnosis of tuberculosis and rifampin resistance in county-level labor atories in Hunan province，China [J]. Chin Med J（Engl），2014，127（21）：3744-3750.
[12] Nimmo C，Doyle R，Burgess C，et al. Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum [J]. Int J Infect Dis，2017，62（7）：44-46.
[13] van Zyl-Smit RN，Binder A，Meldau R， et al. Comparison of quantitative techniques including Xpert MTB/RIF to evaluate Mycobacterial burden [J]. PloS One，2011，6（12）：e28815.
[14] Slavchev G，Michailova L，Markova N. L-form transformation phenomenon in Mycobacteriumtuberculosis associated with drug tolerance to ethambutol [J]. Int J Mycobacteriol，2016，5（4）：454-459.
[15] 杨小猛，赵丹，陈倩瑜，等.结核分枝杆菌L型感染对结核病患者耐药状况的影响[J].临床肺科杂志，2015，20（3）：426-429.
[16] 曹翌明，李丽，孟繁荣，等.中国结核杆菌利福平耐药株rpoB基因531、526、516位点碱基突变特点[J].现代医院，2015，15（7）：7-9，12.
[17] Mboowa G，Namaganda C，Ssengooba W. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert（R）MTB/RIF in Kampala，Uganda：a retrospective study [J]. BMC Infect Dis，2014，14（1）：481.
[18] 高旭，李静，柳清云，等.异质性耐药对结核分枝杆菌表型和基因型耐药检测结果的影响[J].中华结核和呼吸杂志，2014，37（4）：260-265.
[19] 徐礼锋，余旭良，张锋，等.液体MGIT培养联合XpertMTB/RIF快速检测结核分枝杆菌及其耐药性研究[J].中华检验医学杂志，2016，39（4）：272-276.
[20] 张慧慧，熊国亮.SAT技术检测肺结核患者痰标本中结核分枝杆菌的临床应用研究[J].实验与检验医学，2015， 33（4）：407-409.
[21] 葛燕萍，张青.痰标本RNA恒温扩增技术对活动性肺结核的临床诊断价值[J].中国防痨杂志，2016，38（9）：742-746.
2018, Vol. 15 
京公网安备 11010502046598号